PACB Pacific Biosciences of California, Inc. stock chart & analysis
Conviction 36IndustrialsScan · Thu, Nov 19, 2026Pacific Biosciences of California, Inc. (PACB) closed at $1.76 (-4.10%) on Nov 19, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 38, RS Rating 90, -48.9% from its 52-week high, -6.2% year to date. Sector: Industrials · Laboratory Analytical Instruments.
Why PACB moved
From the StockSetups movers recaps that covered PACB, newest first. A recap states what was known that day.
- Close+29.5%
No news headlines are on file for PACB on September 30. The catalyst is unclear. However, given the stock's massive short interest of 49.6 million shares and 6.8 days to cover, a short squeeze is a very plausible explanation.
Top Stock Movers Sept 30, 2026: TGE, CMCT, PACB →
Financials as of Wed, Sep 30, 2026 · quarterly.
PACB technical analysis
Trend
PACB's moving averages are mixed — no clean uptrend or downtrend. It closed 14.2% below the 50-day ($2.05) and 10.0% above the 200-day ($1.60). ADX(14) at 23 points to a moderate trend. It meets 5 of 8 trend-template criteria.
Momentum
RSI(14) is 38, in the bearish half of its range. The MACD histogram is negative. A bearish RSI divergence is in place. A bearish MACD divergence is in place. Its RS Rating of 90 puts its weighted 12-month performance ahead of about 90% of the US market.
Volume and volatility
Volume on the latest session ran 1.3× its 20-day average. It trades about $31.1M a day on average. ATR(14) is $0.2525, 14.4% of price — its typical daily range. Chaikin Money Flow (-0.09) shows distribution.
Key levels
The chart pattern's support is $1.75 and its resistance $3.25. The 52-week range is $1.07 to $3.44; price is 48.9% below the high and 64.0% above the low. The VWAP anchored at the 52-week high is $2.32, above price.
Performance
PACB returned -10.9% (1 week), -18.0% (1 month), +30.0% (3 months), +40.4% (6 months), +6.4% (1 year), -6.2% (year to date).
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
Laboratory Analytical Instruments · Listed 2010 · 485 employees
Insider activity
SEC Form 4 transactions in PACB · open-market 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Van Oene Mark See Remarks · Common Stock · 2026-08-17 | Sell | 26.91K | $30K | 2026-08-17 | 2026-08-18 |
Van Oene Mark See Remarks · Common Stock · 2026-08-10 | Grant | 489.13K | — | 2026-08-10 | 2026-08-11 |
Van Oene Mark See Remarks · Stock Option (right to buy) · 2026-08-10 | Grant | 1.97M | — | 2026-08-10 | 2026-08-11 |
Ericson William W. Director · Stock Option (right to buy) · 2026-06-03 | Grant | 223.49K | $0 | 2026-06-03 | 2026-06-04 |
LIVINGSTON RANDALL S Director · Stock Option (right to buy) · 2026-06-03 | Grant | 223.49K | $0 | 2026-06-03 | 2026-06-04 |
Smith Christopher M Director · Stock Option (right to buy) · 2026-06-03 | Grant | 223.49K | $0 | 2026-06-03 | 2026-06-04 |
MOHR MARSHALL Director · Stock Option (right to buy) · 2026-06-03 | Grant | 223.49K | $0 | 2026-06-03 | 2026-06-04 |
Gibson Christopher Director · Stock Option (right to buy) · 2026-06-03 | Grant | 74.5K | $0 | 2026-06-03 | 2026-06-04 |
ORDONEZ KATHY Director · Stock Option (right to buy) · 2026-06-03 | Grant | 223.49K | $0 | 2026-06-03 | 2026-06-04 |
MILLIGAN JOHN F Director · Stock Option (right to buy) · 2026-06-03 | Grant | 223.49K | $0 | 2026-06-03 | 2026-06-04 |
SEC filings
EDGAR filings in PACB · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.